UPMC Enterprises

UPMC Enterprises is the innovation, commercialization and venture capital arm of UPMC, the health care provider and insurer based in Pittsburgh, Pennsylvania. UPMC formed it in 2014 by bringing its existing work on commercializing health care ideas under one name.^[1][2] Its investments run from new medicines and diagnostic tests to software for hospitals. In January 2020 it committed $1 billion to the life sciences.^[3]

In 2019 UPMC Enterprises became an institutional seed investor in demonpore, inc., the nanopore company that renamed itself Molecular Reality Corporation in 2021. It is one of three backers that Molecular Reality names in public, with the geneticist George Church and the investor and writer Esther Dyson.^[4]

UPMC began as the University of Pittsburgh Medical Center and is affiliated with the University of Pittsburgh Schools of the Health Sciences. In October 2026 its website described it as a $34 billion provider and insurer with more than 40 hospitals and about 100,000 staff, including more than 5,000 employed physicians, and an insurance arm serving more than four million members. Its website also notes that the University of Pittsburgh has ranked among the ten largest recipients of research funding from the National Institutes of Health since 1998.^[5]

The health system's commercial ventures predate the venture arm. UPMC co-founded Evolent, a company that later went public; Stentor, a digital radiology company from its earlier ventures, was bought by Philips; and it counts its own insurer, UPMC Health Plan, as its largest entrepreneurial success.^[1]

UPMC Enterprises dates its founding to 2014, when the health system "rebranded its long-standing work on health care innovation and commercialization" by forming the unit.^[1] By October 2019 it reported that more than 30 technologies, its own and those of startups it had partnered with, were in use at UPMC. Among the young companies it worked with was Abridge, which made a mobile application that let patients record and review their conversations with doctors, and the unit remained an investor in Health Catalyst, a health data company that had gone public.^[1]

On January 14, 2020, UPMC announced that the unit would "deploy $1 billion to develop new drugs, diagnostics and devices by 2024", investing in partners worldwide as well as in Pittsburgh. The sum included $200 million that had already funded a partnership with the University of Pittsburgh on immunotherapy. The same announcement said that UPMC had invested more than $800 million in its entrepreneurial efforts up to then, mostly in digital health, and that they had returned more than $1.5 billion.^[3]

In 2026 UPMC Enterprises described its mission as being "to transform ideas into thriving businesses and Life Changing Medicine", the last three words being UPMC's slogan.^[2] Its work is divided into focus areas:

• Translational Sciences, "Investing in and supporting the development and commercialization of cutting-edge diagnostics and therapeutics". The group pairs scientific and clinical expertise with investment and commercializes research that comes mainly from the University of Pittsburgh.^[2][1]
• Digital Solutions, "Providing strategic, technical, and financial insights to build innovative products and launch novel technologies".^[2]
• Corporate initiatives, including the Pittsburgh Health Data Alliance, a collaboration of UPMC, Carnegie Mellon University and the University of Pittsburgh, and the Center for Connected Medicine, a source of information and events on digital health.^[2]

The companies shown on its website in October 2026, more than 40 of them, included Abridge, the drug developers Cerevance and Werewolf Therapeutics, and Ultromics.^[6]

Molecular Reality describes UPMC Enterprises as its institutional seed investor, from 2019.^[4] The company was then called demonpore, inc., after Maxwell's demon, and was developing sliding occlusion, a way of making a nanopore whose size can be changed while it is in use. Its records list, for the months before the investment, the first use of its pores on a real sample, when the founder Kent Kemmish bled into a flow cell in late 2018; autonomous pore declogging in December 2018; and the gating and oversampling of individual cells and nanoparticles in January 2019.^[4][7] Kemmish's patent on the method was then pending; it was granted in 2021.^[8] In 2018 the company had an office on Edison Way in Menlo Park, California, and it describes its founding team as including alumni of Synthego, Oxford Nanopore and the Harvard Nanopore Group.^[4][9]

In the years after the investment the company built the demonpore 64, a prototype reader styled as a 1980s game console (2020 and 2021); took the name Molecular Reality Corporation (2021); began streaming the current through a pore to the public from a bench in Arizona (May 2026); and released the design of its own instrument, the MR1 Nanopore Reader, as open-source hardware (October 2026).^[4][10]

Of the company's two other named backers, Church, a co-inventor on a 1995 patent application for reading polymers as they pass through a pore, was also the first formal member of its scientific advisory board.^[4][11] Brownian Business Daily named all three backers in its 2026 account of the company's first ten years.^[12]

• Rain of blood (demonpore)
• Patent US 10,908,144
• Complete blood count

• Official website